

Table 14.1.2.1
Number of Subjects in Each Analysis Set by Baseline SARS-CoV-2 Status
Randomization Set

	Baseline SARS-CoV-2 Negative			Baseline SARS-CoV-2 Positive			Overall		
	Placebo	mRNA-1273	Total	Placebo	mRNA-1273	Total	Placebo	mRNA-1273	Total
Randomization Set [1]	14370	14312	28682	334	341	675	15210	15208	30418
Full Analysis Set, n (%) [1]	14370 (100)	14312 (100)	28682 (100)	334 (100)	341 (100)	675 (100)	15170 (99.7)	15180 (99.8)	30350 (99.8)
Modified Intent-to-Treat (mITT) Set, n (%) [1]	14370 (100)	14312 (100)	28682 (100)	0	0	0	14370 (94.5)	14312 (94.1)	28682 (94.3)
Per-Protocol (PP) Set, n (%) [1]	13883 (96.6)	13934 (97.4)	27817 (97.0)	0	0	0	13883 (91.3)	13934 (91.6)	27817 (91.4)
Safety Set [2]	14366	14316	28682	334	341	675	15165	15184	30350
Solicited Safety Set, n (%) [2]	14363 (>99.9)	14309 (>99.9)	28672 (>99.9)	334 (100)	340 (99.7)	674 (99.9)	15162 (>99.9)	15176 (>99.9)	30339 (>99.9)
First Injection Solicited Safety Set, n (%) [2]	14356 (>99.9)	14301 (99.9)	28657 (>99.9)	334 (100)	340 (99.7)	674 (99.9)	15154 (>99.9)	15167 (99.9)	30322 (>99.9)
Second Injection Solicited Safety Set, n (%) [2]	13252 (92.2)	13286 (92.8)	26538 (92.5)	213 (63.8)	203 (59.5)	416 (61.6)	13870 (91.5)	13947 (91.9)	27817 (91.7)

[1] Numbers are based on planned treatment group and percentages are based on the number of randomized subjects.

[2] Numbers are based on actual treatment group and percentages are based on the number of safety subjects.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\EUA Nov 2020\TLF\t14010201.sas 21NOV2020 01:07